Clearpoint Neuro, INC 10-Q quarterly reports

ClearPoint Neuro, Inc. reported an 18% increase in Q2 2026 revenue to $10.9 million, but also a significant widening of its net loss to $11.3 million, driven by increased operating expenses.

ClearPoint Neuro reports 43% revenue growth in Q1 2026, driven by IRRAS acquisition and expanded neurosurgical product sales.

ClearPoint Neuro, Inc. reported a 9% increase in total revenue for the third quarter of 2025, alongside an expanded net loss and the announcement of a strategic merger with IRRAS Holdings, Inc.

ClearPoint Neuro, Inc. reported a 17% increase in total revenue for Q2 2025, reaching $9.2 million, but saw its net loss widen by 32% to $5.8 million.

ClearPoint Neuro's Q1 2025 revenue increased by 11% year-over-year, driven by growth in neurosurgery navigation and biologics and drug delivery sectors, despite a net loss of $6.0 million.

ClearPoint Neuro saw a significant increase in product revenue during the third quarter of 2024, primarily driven by growth in its biologics and neurosurgery segments.

ClearPoint Neuro saw a significant increase in revenue during the second quarter of 2024, primarily driven by product sales and growth in its biologics and drug delivery partnerships.

ClearPoint Neuro's first quarter of 2024 saw a significant revenue increase driven by growth in biologics and drug delivery services and capital equipment sales.